Amylin and Biocon to develop peptide therapeutic
This article was originally published in Scrip
The biotech companies, Biocon and Amylin Pharmaceuticals have entered into an agreement to jointly develop, manufacture and commercialise a novel peptide therapeutic for the potential treatment of diabetes.
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.